Indian Journal of Ophthalmology

: 1982  |  Volume : 30  |  Issue : 4  |  Page : 315--316

Clinical trial of ultralan ophthalmicum oleosum

BT Maskati, RP Jehangir, HL Trivedi 
 Department of Ophthalmology, K. E. M. Hospital, Mumbai, India

Correspondence Address:
B T Maskati
111/112 Summer-ville, Bhoolabhai Desai Road, Mumbai 26

How to cite this article:
Maskati B T, Jehangir R P, Trivedi H L. Clinical trial of ultralan ophthalmicum oleosum.Indian J Ophthalmol 1982;30:315-316

How to cite this URL:
Maskati B T, Jehangir R P, Trivedi H L. Clinical trial of ultralan ophthalmicum oleosum. Indian J Ophthalmol [serial online] 1982 [cited 2020 Apr 2 ];30:315-316
Available from:

Full Text

After introducing 16 alpha-methyl group and substituting a flourine atom in the 6 alpha position, in corticosterone, a steroid with a pronounced antiinflammatory activity labelled as fluocortolone was created. It is an active ingredient of Ultralan.

In the present trial 56 patients with various inflammatory disorders affecting the anterior segment of the eye were treated with ultralan ophthalmicum olesoum with good results in 37 and fair in 19 patients.

Ultralan eye drops contain 0.5% fluocorto­-one trimethylacetate and 0.2% chlorampheni­col in castor oil base.


A clinical trial with "Ultralan Ophthal­micum Oleosum" was conducted on 64 patients of King Edward VII Memorial Hospital, Bombay. The patients were selected at random with anterior segment involvement [Table 1]. Fiftysix patients came for regular follow up while 8 did not come who were excluded from the trial.

On the first visit a complete record of the signs and symptoms was prepared. Anterior segment of the eye was examined with help of torch, binocular loupe and slit lamp.

There were 36 male and 20 female patients included in the study, with various age groups,

Patients were instructed to instill one drop of Ultralan 4 times a day initially and then gradually tapered depending on the recovery. Patients were asked to come for follow up on alternate days till the lesions and symptoms disappeared. Subsequently patients were asked to come periodically for check up at 15 days intervals for 2 months and any recurrence of the lesions, if present was recorded.

In six bilateral cases, one eye was treated with either hydrocortisone or betamethasone preparation and the other with Ultralan. The eye which was more severely affected was treated with Ultralan in cases of unequal affection.

Five patients included in the trial were treated with other steroid preparations initially. Since the lesions persisted, they were put on Ultralan.


In the present study the results were good in 37 (66%) and fair in 19 (34%)patients

Following criteria was used to judge the results

Disappearance of all lesions .. Good

Disappearance of 75% of

lesions .. Fair

- No improvement or less than

50% in 3 days .. Poor

The reversible lesions and signs like phlycten, ciliary injection, conjunctival con­junctival congestion, aqueous flare, keratic precipitates, corneal vascularisation etc. were considered and not the irreversible lesions like corneal opacities, complicated cataract, dense posterior synechiae etc.

In six bilateral cases, the eye which was treated with Ultralan improved earlier than the eye which was treated with other steroid preparation.

In the 5 patients the lesions persisted after treatment with other steroid preparations but disappeared after Ultralan instillation.

Intra-ocular tension, as checked with Schiotz tonometer, was not increased in any of the 6 patients who received treatment for 25 days to 2 months duration The frequency of instillation of Ultralan drops was 4 times a day for one week, thrice a day for one week, and twice a day subsequently.

There were no side effects observed with the drug, and except for stickiness and foul smell due to the castor oil base, no other complaints were received regarding the drug.


We thank Dr. C.K. Deshpande, the Dean, K.E.M. Hospital, Bombay, for allowing us to conduct the trial, and Dr. V.N. Mehta for Schering Division of German Remedies Ltd, for providing us the drug Ultralan Ophthal­micum Oleosum.